Akebia Therapeutics, Inc. has announced the issuance of a new U.S. patent for Vafseo® (vadadustat), extending the drug’s intellectual property protection until January 18, 2043. The patent, granted by the U.S. Patent and Trademark Office, relates specifically to a method of treatment involving drug-drug interactions with vadadustat. This addition strengthens Akebia’s vadadustat patent portfolio and is eligible for listing in the FDA’s Orange Book, which can provide additional market exclusivity benefits.
John P. Butler, CEO of Akebia Therapeutics, expressed confidence that Vafseo could become the standard of care for treating anemia associated with chronic kidney disease (CKD). He highlighted the drug’s compelling clinical outcomes as a foundation for this belief. Vafseo received FDA approval in March 2024 and is notable as the only oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor currently available in the United States for patients undergoing dialysis.
Vafseo functions by activating the body’s response to hypoxia, stimulating erythropoietin production, and increasing hemoglobin and red blood cell counts. This mechanism addresses anemia in CKD patients, a population with significant unmet medical needs.
Despite its unique market position, Vafseo’s safety profile raises important considerations. The drug carries increased risks of severe cardiovascular events, including death, myocardial infarction, stroke, and thrombotic vascular events. These risks necessitate careful patient monitoring and dosing adjustments. Additionally, concerns about hepatotoxicity and hypertension have been noted, potentially limiting prescriber enthusiasm.
Moreover, clinical data have not demonstrated improvements in patient quality of life, fatigue, or overall well-being, factors that may influence both patient and healthcare provider acceptance of Vafseo as a treatment option.
Vafseo has been commercially available in the U.S. since January 2025, following its FDA approval. Akebia Therapeutics continues to focus on delivering innovative biopharmaceutical solutions aimed at improving outcomes for individuals affected by kidney disease.
In related corporate activity, insider trading data reveals that Erik Ostrowski, Akebia’s Senior Vice President, Chief Financial Officer, Chief Business Officer, and Treasurer, sold 56,019 shares of $AKBA stock over the past six months, with no insider purchases reported during this period.
This patent grant marks a significant milestone for Akebia’s intellectual property strategy, potentially enhancing Vafseo’s competitive position in the anemia treatment market for years to come.
Akebia Therapeutics Secures Extended Patent Protection for Vafseo® Through 2043 Akebia Therapeutics has been granted a U.S. patent extending intellectual property protection for its anemia treatment Vafseo® (vadadustat) until January 18, 2043. The patent, covering methods addressing drug-drug inter... Read the full IIPLA article: https://iipla.org/news/akebia-therapeutics-secures-extended-patent-protection-for-vafseo-through-2043